Patent Grant
11278665
The present invention relates generally to delivery of a therapeutic substance to a subject, and more specifically to wearable drug delivery devices.
Pumps are often used in the medical industry for delivering therapeutic substances, e.g., drugs, to subjects. Therapeutic substances such as saline solution, insulin, antibiotics, and chemotherapy drugs may all be delivered to a subject with medical pumps. While hospitalization is required for delivery of some therapeutic substances, other therapeutic substances, such as for example insulin, do not require that the subject be in the hospital. Medical pumps enable patients to go about their daily lives while receiving a therapeutic substance.
Apparatus, such as for example a wearable medical patch pump, is provided for delivering a therapeutic substance to a subject in a precise, controlled, and consistent manner. In accordance with some applications of the present invention, the apparatus includes a therapeutic substance reservoir for holding the therapeutic substance, and an electromechanical pumping assembly coupled to the reservoir for delivery of the therapeutic substance to the subject. The electromechanical pumping assembly is shaped to define a pump chamber having a therapeutic substance inlet and a therapeutic substance outlet. The therapeutic substance is received from the reservoir into the pump chamber through the therapeutic substance inlet during a first pumping phase, and is delivered from the pump chamber to the subject through the therapeutic substance outlet during a second pumping phase. The electromechanical pumping assembly uses a plunger that is disposed such that therapeutic substance in the pump chamber is in direct contact with the plunger. Control circuitry drives the plunger to (a) draw the therapeutic substance into the pump chamber during the first pumping phase and (b) deliver the therapeutic substance from the pump chamber in a plurality of discrete motions of the plunger during the second pumping phase, thereby delivering the therapeutic substance to the subject in a plurality of controlled and discrete dosages throughout the second pumping phase. A cycle of alternating the first and second pumping phases may be repeated as many times as desired.
There is therefore provided, in accordance with some applications of the present invention, apparatus for delivering a therapeutic substance to a subject, the apparatus including:
a therapeutic substance reservoir configured to hold a therapeutic substance; and
an electromechanical pumping assembly coupled to the reservoir, the pumping assembly shaped to define a pump chamber having:
the pumping assembly including:
For some applications, the control circuitry is configured to drive the plunger to draw the therapeutic substance into the pump chamber during the first pumping phase in a single motion of the plunger.
For some applications, the control circuitry is configured to drive the plunger to draw the therapeutic substance into the pump chamber during the first pumping phase in one or more discrete expansion motions of the plunger, a duration of each expansion motion being longer than a duration of any one of the plurality of discrete motions of the plunger during the second pumping phase.
For some applications, the control circuitry is configured to drive the plunger such that respective durations of the plurality of discrete motions of the plunger during the second pumping phase are equal.
For some applications, the control circuitry is configured to drive the plunger such that a duration of the first pumping phase and a duration of the second pumping phase are unequal.
For some applications, a ratio of the duration of the second pumping phase to the duration of the first pumping phase is at least 10:1.
For some applications, a ratio of a duration of the second pumping phase to a duration of the first pumping phase is between 5:1 and 50:1.
For some applications, the apparatus further includes (a) an inlet valve coupled to the therapeutic substance inlet, and configured to be opened and closed such that when the inlet valve is open there is fluid communication between the reservoir and the pump chamber and when the inlet valve is closed there is no fluid communication between the reservoir and the pump chamber, and (b) an outlet valve coupled to the therapeutic substance outlet, and configured to be opened and closed such that when the outlet valve is open there is fluid communication between the pump chamber and the subject and when the outlet valve is closed there is no fluid communication between the pump chamber and the subject, and the control circuitry is configured to:
For some applications, the inlet valve is a bidirectional valve, and the outlet valve is a unidirectional valve.
For some applications:
the control circuitry is configured to provide a valve-check phase in which the inlet valve and the outlet valve are closed, and to drive the plunger during the valve-check phase to advance in the pump chamber, and
the apparatus further includes a pressure sensor disposed between the pump chamber and either one of the inlet valve and the outlet valve, and configured to measure a change in pressure inside the pump chamber as the plunger advances in the pump chamber during the valve-check phase.
For some applications, the control circuitry is configured to provide the valve-check phase between the first pumping phase and the second pumping phase.
For some applications, the control circuitry is configured to, during a negative-pressure reduction phase between the first pumping phase and the second pumping phase, maintain the inlet valve open and the outlet valve closed following the drawing of the therapeutic substance into the pump chamber.
For some applications, the control circuitry is configured to reduce an amplitude of negative pressure in the pump chamber by driving the plunger to push on the therapeutic substance in the pump chamber during the negative-pressure reduction phase.
For some applications, the control circuitry is configured not to drive the plunger to push on the therapeutic substance in the pump chamber during the negative-pressure reduction phase.
For some applications, a duration of the negative-pressure reduction phase is 0.1-5 seconds.
For some applications, a ratio of a duration of the negative-pressure reduction phase to a duration of the first pumping phase is between 1:10 and 5:1.
For some applications, the ratio of the duration of the negative-pressure reduction phase to the duration of the first pumping phase is between 1:10 and 1:1.
For some applications:
the therapeutic substance reservoir is configured to hold the therapeutic substance in a soluble solid state or a soluble gaseous state,
the apparatus further includes a solvent reservoir configured to hold a solvent the soluble therapeutic substance,
the pumping assembly is further shaped to define a mixing chamber having (a) a first mixing chamber inlet through which the therapeutic substance is received from the reservoir into the mixing chamber during the first pumping phase, and (b) a second mixing chamber inlet through which the solvent is received from the solvent reservoir into the mixing chamber during the first pumping phase, such that a therapeutic substance solution is formed within the mixing chamber, and
the therapeutic substance inlet of the pump chamber is disposed between the mixing chamber and the pump chamber such that the therapeutic substance solution is received from the mixing chamber through the therapeutic substance inlet into the pump chamber during the first pumping phase.
For some applications:
the therapeutic substance reservoir is a first therapeutic substance reservoir and the therapeutic substance is a first therapeutic substance,
the apparatus further includes a second therapeutic substance reservoir configured to hold a second therapeutic substance, and
the pump chamber has a second therapeutic substance inlet through which the second therapeutic substance is received from the second reservoir into the pump chamber during the first pumping phase of the pumping assembly.
For some applications:
the pumping assembly is further shaped to define a mixing chamber having (a) a first mixing chamber inlet through which the first therapeutic substance is received from the first reservoir into the mixing chamber during the first pumping phase, and (b) a second mixing chamber inlet through which the second therapeutic substance is received from second reservoir into the mixing chamber during the first pumping phase, and
the therapeutic substance inlet of the pump chamber is disposed between the mixing chamber and the pump chamber such that a mixture of the first and second therapeutic substances is received from the mixing chamber through the therapeutic substance inlet into the pump chamber during the first pumping phase.
For some applications:
the first therapeutic substance reservoir is configured to hold the first therapeutic substance in a soluble solid state or a soluble gaseous state,
the apparatus further includes a solvent reservoir configured to hold a solvent for the first therapeutic substance,
the pumping assembly is further shaped to define a mixing chamber having (a) a first mixing chamber inlet through which the soluble therapeutic substance is received from the first reservoir into the mixing chamber during the first pumping phase, and (b) a second mixing chamber inlet through which the solvent is received from the solvent reservoir into the mixing chamber during the first pumping phase such that a therapeutic substance solution is formed within the mixing chamber, and
the therapeutic substance inlet of the pump chamber is a first therapeutic substance inlet valve through which the therapeutic substance solution is received from the mixing chamber into the pump chamber during the first pumping phase, the pump chamber further having a second therapeutic substance inlet valve through which the second therapeutic substance is received from the second, reservoir into the pump chamber during the first pumping phase.
There is further provided, in accordance with some applications of the present invention, a method of delivering a therapeutic substance to a subject, the method including:
using a plunger to draw the therapeutic substance front a therapeutic substance reservoir into a pump chamber of an electromechanical pumping assembly during a first pumping phase,
subsequently, delivering the therapeutic substance from the pump chamber to the subject in a plurality of discrete dosages by delivering the therapeutic substance from the pump chamber in a plurality of discrete motions of the plunger during a second pumping phase, the pump chamber being in fluid communication with the subject and not in fluid communication with the reservoir during the second pumping phase.
For some applications:
(a) using the plunger to draw the therapeutic substance from the therapeutic substance reservoir into the pump chamber includes (i) opening an inlet valve disposed in a therapeutic substance inlet of the pump chamber, through which the therapeutic substance is received from the reservoir into the pump chamber during the first pumping phase, and (ii) closing an outlet valve disposed in a therapeutic substance outlet of the pump chamber, through which the therapeutic substance is delivered from the pump chamber to the subject during the second pumping phase, and
(b) delivering the therapeutic substance from the pump chamber to the subject includes closing the inlet valve and opening the outlet valve.
For some applications, the method further includes reducing an amplitude of negative pressure in the pump chamber during a negative-pressure reduction phase between the first pumping phase and the second pumping phase, by maintaining the pump chamber in fluid communication with the reservoir and not in fluid communication with the subject following the drawing of the therapeutic substance into the pump chamber.
For some applications, using the plunger to draw the therapeutic substance from the therapeutic substance reservoir into the pump chamber includes using the plunger to draw the therapeutic substance from the therapeutic substance reservoir into the pump chamber in a single motion of the plunger.
For some applications, using the plunger to draw the therapeutic substance from the therapeutic substance reservoir into the pump chamber includes using the plunger to draw the therapeutic substance from the therapeutic substance reservoir into the pump chamber in one or more discrete expansion motions of the plunger, wherein each expansion motion is longer in duration than any one of the plurality of discrete motions of the plunger during the second pumping phase.
There is further provided, in accordance with some applications of the present invention, apparatus for delivering a therapeutic substance to a subject, the apparatus including:
a therapeutic substance reservoir configured to hold a therapeutic substance; and
an electromechanical pumping assembly coupled to the reservoir, the pumping, assembly shaped to define a pump chamber having:
the pumping assembly including:
For some applications, the apparatus further includes a lever arm coupled to the moving-coil motor and the toothed wheel, and configured to translate the discrete movement of the coil into the discrete rotational motion of the toothed wheel.
The present invention will be more fully understood from the following detailed description of applications thereof, taken together with the drawings, in which:
Reference is now made to
When apparatus 20 is assembled and ready for use, an electromechanical pumping assembly 26 is coupled to therapeutic substance reservoir 24. Electromechanical pumping assembly 26 is shaped to define a rigid pump chamber 28 that has (a) a therapeutic substance inlet 30, through which therapeutic substance 22 is received from reservoir 24 into pump chamber 28, and (b) a therapeutic substance outlet 32, through which therapeutic substance 22 is delivered from pump chamber 28 to the subject. For some applications, pump chamber 28 may hold a volume of therapeutic substance 22 of at least 5 microliters and/or less than 100 microliters.
A plunger 34 is disposed in apparatus 20 such that therapeutic substance 22 in pumping chamber 28 is in direct contact with plunger 34 (such as is shown in
Reference is now made to
For some applications, control circuitry 36 is configured to drive plunger 34 to draw therapeutic substance 22 into pump chamber 28 in a single motion of plunger 34, e.g., plunger 34 is pulled back in a single motion to draw a volume of therapeutic substance 22 into pump chamber 28 during the first pumping phase. Alternatively, control circuitry 36 may be configured to drive plunger 34 to draw therapeutic substance 22 into pump chamber 28 in one or more discrete expansion motions of plunger 34, e.g., plunger 34 may be pulled half way out in one motion and then the rest of the way out in a second separate motion. In this case, a duration of some or all expansion motions of plunger 34 during the first pumping phase are typically longer than a duration of any one of the plurality of discrete motions of plunger 34 during the second pumping phase.
For some applications, control circuitry 36 drives plunger 34 such that a duration of the first pumping phase and a duration of the second pumping phase are unequal. For example, a duration of the second pumping phase may be at least 10 times, e.g., 30 times, e.g., 50 times, longer than a duration of the first pumping phase. For some applications, a duration of the second pumping phase is at least 5 and/or less than 50 times longer than a duration of the first pumping phase.
Typically, the direction of flow of the therapeutic substance 22 within electromechanical pumping assembly 26 is controlled by a set of valves. An inlet valve 42 is coupled to therapeutic substance inlet 30, and configured to be opened and closed such that when inlet valve 42 is open there is fluid communication between reservoir 24 and pump chamber 28, and when inlet valve 42 is closed there is no fluid communication between reservoir 24 and pump chamber 28. An outlet valve 44 is coupled to therapeutic substance outlet 32 and configured to be opened and closed such that when outlet valve 44 is open there is fluid communication between pump chamber 28 and the subject, and when outlet valve 44 is closed there is no fluid communication between pump chamber 28 and the subject.
During the first pumping phase, control circuitry 36 is configured to open inlet valve 42, close outlet valve 44 and drive plunger 34 to draw therapeutic substance 22 from reservoir 24 into pump chamber 28, e.g., control circuitry 36 sets inlet valve 42 and outlet valve 44 such that therapeutic substance 22 can flow only between reservoir 24 and pump chamber 28. Thus, as plunger 34 is drawn hack, therapeutic substance 22 is drawn into pump chamber 28. Subsequently, during the second pumping phase, control circuitry 36 is configured to close inlet valve 42, open outlet valve 44 and drive plunger 34 to deliver therapeutic substance 22 from pump chamber 28 in a plurality of discrete motions of plunger 34. For example, control circuitry 36 may set inlet valve 42 and outlet valve 44 such that therapeutic substance 22 can flow only between pump chamber 28 and the subject, and plunger 34 is incrementally pushed back into pump chamber 28 in a plurality of discrete motions thereby delivering therapeutic substance 22 to the subject in a plurality of discrete dosages.
Reference is now made to
Reference is now made to
Reference is now made to
For some applications, during the negative-pressure reduction phase, control circuitry 36 is configured to further reduce the amplitude of negative pressure in pump chamber 28 by driving plunger 34 to push on therapeutic substance 22 in pump chamber 28, causing some of therapeutic substance 22 to flow back into reservoir 24 through open inlet valve 42. Alternatively, control circuitry 36 may be configured not to actively drive plunger 34 to push on therapeutic substance 22, but rather the amplitude of negative pressure in pump chamber 28 may be reduced by plunger 34 naturally being sucked back into pump chamber 28 by the negative pressure, causing some of therapeutic substance 22 to flow back into reservoir 24 through open inlet valve 42. Arrow 52 in
For some applications, a duration of the negative-pressure reduction phase may range from 10 times shorter than the duration of the first pumping phase to 5 times longer than the duration of the first pumping phase. Typically, the negative-pressure reduction phase is shorter than the first pumping phase, i.e., the duration of the negative-pressure reduction phase ranges from 10 times shorter than the duration of the first pumping phase to substantially equal to the duration of the first pumping phase. For example, the duration of the negative-pressure reduction phase may be 0.1-5 seconds.
Reference is now made to
Reference is now made to
Reference is now made to
Reference is now made to
Reference is now made to
Driving the rotation of cam 70 is a toothed wheel 72 that is driven to rotate through a plurality of discrete rotational motions by a moving-coil motor 74. Toothed wheel 72 is coupled to cam 70 and configured to rotate cam 70 in a plurality of discrete motions of cam 70, each discrete motion of cam 70 corresponding to a discrete rotational motion of the toothed wheel. Moving-coil motor 74 operates such that as current is applied to a coil 76 of moving-coil motor 74, coil 76 undergoes a discrete motion in a first direction. Applying an opposite current to coil 76 causes another discrete motion of coil 76 in a second direction opposite the first discrete motion. Therefore, alternating the current applied to coil 76 causes coil 76 to undergo alternating discrete motions, e.g., to move linearly back and forth. Arrow 75 in
For example, a lever arm 78 may be coupled to moving-coil motor 74 and toothed wheel 72 such that as coil 76 undergoes a discrete movement, lever arm 78 pulls on a tooth 80 of toothed wheel 72 so as to rotate toothed wheel 72 through one discrete rotational motion. As the current is reversed, coil 76 may return to a starting position so as to allow lever arm 78 to catch a next tooth 82 of toothed wheel 72. Current in the first direction causes coil 76 to repeat the discrete movement, causing toothed wheel 72 to move through a next discrete rotational motion. As coil 76 moves back and forth, toothed wheel 72 is incrementally rotated in a plurality of discrete rotational motions, thereby rotating cam 70 in a respective plurality of discrete rotational motions so as to drive plunger 34 to deliver therapeutic substance 22 from pump chamber 28 to the subject in a plurality of discrete motions of plunger 34.
The accuracy of this system is defined by full discrete motions of coil 76 and not by analog continuous motions, as in many other drive systems. The discrete motions of coil 76, which drive toothed wheel 72 to rotate in discrete rotational motions, provide equal bolus steps making the flow of therapeutic substance uniform, i.e., accurate and continuous with little variation. The only control parameter that is used for different flow rates is the time per step, which can be controlled with software.
Opening and closing the inlet and outlet valves may similarly be controlled using a cam and moving-coil motor. For some applications, the same cam 70 and moving-coil motor 74 that are used to control plunger 34 are coupled to the valves and configured to open and close the respective valves in accordance with the various pumping phases as described hereinabove. Alternatively or additionally, some or all of the valves may be coupled to a dedicated valve cam and separate moving-coil motor for controlling the timing of the opening and closing of the respective valves.
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
The present application is the US national stage application of PCT/IL2017/051276, filed Nov. 22, 2017, which published as PCT Publication WO 2018/096534 to Zidon, and which claims the priority of U.S. 62/425,105 to Tzidon, filed Nov. 22, 2016 entitled, “Methods circuits assemblies devices and functionally associated machine associated code for wearable drug delivery systems,” which is incorporated herein by reference. The above-referenced applications are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IL2017/051276 | 11/22/2017 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2018/096534 | 5/31/2018 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3469578 | Bierman | Sep 1969 | A |
| 3993061 | O'Leary | Nov 1976 | A |
| 4511355 | Franetzki et al. | Apr 1985 | A |
| 4585435 | Vaillancourt | Apr 1986 | A |
| 4909790 | Tsujikawa et al. | Mar 1990 | A |
| 4968301 | Di Palma et al. | Nov 1990 | A |
| 5085656 | Polaschegg | Feb 1992 | A |
| 5129884 | Dysarz | Jul 1992 | A |
| 5178610 | Tsujikawa et al. | Jan 1993 | A |
| 5207645 | Ross et al. | May 1993 | A |
| 5242406 | Gross et al. | Sep 1993 | A |
| 5242411 | Yamamoto et al. | Sep 1993 | A |
| 5324258 | Rohrbough | Jun 1994 | A |
| 5439355 | Jimison | Aug 1995 | A |
| 5708367 | Tousson | Jan 1998 | A |
| 5785688 | Joshi et al. | Jul 1998 | A |
| 5897530 | Jackson | Apr 1999 | A |
| 5919167 | Mulhauser et al. | Jul 1999 | A |
| 5993423 | Choi | Nov 1999 | A |
| 6086561 | Kriesel | Jul 2000 | A |
| 6146109 | Davis et al. | Nov 2000 | A |
| 6171276 | Lippe et al. | Jan 2001 | B1 |
| 6186982 | Gross et al. | Feb 2001 | B1 |
| 6227807 | Chase | May 2001 | B1 |
| 6248093 | Moberg | Jun 2001 | B1 |
| 6293159 | Kriesel et al. | Sep 2001 | B1 |
| 6362591 | Moberg | Mar 2002 | B1 |
| 6468261 | Small et al. | Oct 2002 | B1 |
| 6485461 | Mason et al. | Nov 2002 | B1 |
| 6485465 | Moberg et al. | Nov 2002 | B2 |
| 6530217 | Yokota et al. | Mar 2003 | B1 |
| 6530900 | Daily et al. | Mar 2003 | B1 |
| 6542350 | Rogers | Apr 2003 | B1 |
| 6555986 | Moberg | Apr 2003 | B2 |
| 6656158 | Mahoney et al. | Dec 2003 | B2 |
| 6656159 | Flaherty | Dec 2003 | B2 |
| 6659980 | Moberg et al. | Dec 2003 | B2 |
| 6669669 | Flaherty et al. | Dec 2003 | B2 |
| 6673035 | Rice et al. | Jan 2004 | B1 |
| 6680597 | Catellani et al. | Jan 2004 | B1 |
| 6699218 | Flaherty et al. | Mar 2004 | B2 |
| 6740059 | Flaherty | May 2004 | B2 |
| 6749403 | Bryant et al. | Jun 2004 | B2 |
| 6853160 | Gandel et al. | Feb 2005 | B1 |
| 6979316 | Rubin et al. | Dec 2005 | B1 |
| 7029455 | Flaherty | Apr 2006 | B2 |
| 7052251 | Nason et al. | May 2006 | B2 |
| 7115108 | Wilkinson et al. | Oct 2006 | B2 |
| 7137964 | Flaherty | Nov 2006 | B2 |
| 7144384 | Gorman et al. | Dec 2006 | B2 |
| 7278981 | Ellingboe et al. | Oct 2007 | B2 |
| 7303549 | Flaherty et al. | Dec 2007 | B2 |
| 7390314 | Stutz, Jr. et al. | Jun 2008 | B2 |
| 7442186 | Blomquist | Oct 2008 | B2 |
| 7455664 | Fleury et al. | Nov 2008 | B2 |
| 7466092 | Prudham | Dec 2008 | B2 |
| 7503278 | Sigg et al. | Mar 2009 | B2 |
| 7524304 | Genosar | Apr 2009 | B2 |
| 7530964 | Lavi et al. | May 2009 | B2 |
| 7556623 | Lyman et al. | Jul 2009 | B2 |
| 7591448 | Martin et al. | Sep 2009 | B2 |
| 7621893 | Moberg et al. | Nov 2009 | B2 |
| 7682338 | Griffin | Mar 2010 | B2 |
| 7736338 | Kavazov et al. | Jun 2010 | B2 |
| 7766873 | Moberg et al. | Aug 2010 | B2 |
| 7771412 | Anderson et al. | Aug 2010 | B2 |
| 7887505 | Flaherty | Feb 2011 | B2 |
| 7892206 | Moberg et al. | Feb 2011 | B2 |
| 7918825 | O'connor et al. | Apr 2011 | B2 |
| 7918843 | Genosar et al. | Apr 2011 | B2 |
| 7931643 | Olsen et al. | Apr 2011 | B2 |
| 7937831 | Sigg et al. | May 2011 | B2 |
| 7976505 | Hines et al. | Jul 2011 | B2 |
| 7981085 | Ethelfeld | Jul 2011 | B2 |
| 8062253 | Nielsen et al. | Nov 2011 | B2 |
| 8062257 | Moberg et al. | Nov 2011 | B2 |
| 8065096 | Moberg et al. | Nov 2011 | B2 |
| 8072209 | Jerance et al. | Dec 2011 | B2 |
| 8081069 | Haueter et al. | Dec 2011 | B2 |
| 8088096 | Lauchard et al. | Jan 2012 | B2 |
| 8105280 | Iddan et al. | Jan 2012 | B2 |
| 8128597 | Cross et al. | Mar 2012 | B2 |
| 8129474 | Ohbi | Mar 2012 | B2 |
| 8140275 | Campbell et al. | Mar 2012 | B2 |
| 8152779 | Cabiri et al. | Apr 2012 | B2 |
| 8172804 | Bikovsky | May 2012 | B2 |
| 8182447 | Moberg et al. | May 2012 | B2 |
| 8202250 | Stutz, Jr. | Jun 2012 | B2 |
| 8222777 | Loussert et al. | Jul 2012 | B2 |
| 8226610 | Edwards et al. | Jul 2012 | B2 |
| 8231572 | Carter et al. | Jul 2012 | B2 |
| 8246573 | Ali | Aug 2012 | B2 |
| 8267893 | Moberg et al. | Sep 2012 | B2 |
| 8281656 | Schnidrig | Oct 2012 | B2 |
| 8285328 | Caffey et al. | Oct 2012 | B2 |
| 8294561 | Strahm et al. | Oct 2012 | B2 |
| 8298171 | Ishikawa et al. | Oct 2012 | B2 |
| 8303535 | Both et al. | Nov 2012 | B2 |
| 8347807 | Sigg et al. | Jan 2013 | B2 |
| 8372045 | Needle et al. | Feb 2013 | B2 |
| 8427095 | Bilat et al. | Apr 2013 | B2 |
| 8435214 | Gray et al. | May 2013 | B2 |
| 8444592 | Williams et al. | May 2013 | B2 |
| 8449502 | Pratt et al. | May 2013 | B2 |
| 8465468 | Pettis et al. | Jun 2013 | B1 |
| 8467980 | Campbell et al. | Jun 2013 | B2 |
| 8480622 | Kawamura | Jul 2013 | B2 |
| 8483980 | Moberg et al. | Jul 2013 | B2 |
| 8486018 | Kamen et al. | Jul 2013 | B2 |
| 8502426 | Loussert et al. | Aug 2013 | B2 |
| 8523803 | Favreau | Sep 2013 | B1 |
| 8603026 | Favreau | Dec 2013 | B2 |
| 8603027 | Favreau | Dec 2013 | B2 |
| 8617110 | Moberg et al. | Dec 2013 | B2 |
| 8636696 | Ross et al. | Jan 2014 | B2 |
| 8647074 | Moberg et al. | Feb 2014 | B2 |
| 8647296 | Moberg et al. | Feb 2014 | B2 |
| 8668672 | Moberg et al. | Mar 2014 | B2 |
| 8681010 | Moberg et al. | Mar 2014 | B2 |
| 8702656 | Kamen et al. | Apr 2014 | B2 |
| 8708959 | Haase | Apr 2014 | B2 |
| 8708994 | Pettis et al. | Apr 2014 | B2 |
| 8729912 | Cefai et al. | May 2014 | B2 |
| 8752570 | Donahue | Jun 2014 | B2 |
| 8784403 | Cefai et al. | Jul 2014 | B2 |
| 8795234 | Kadamus et al. | Aug 2014 | B2 |
| 8808269 | Bazargan et al. | Aug 2014 | B2 |
| 8821432 | Unverdorben | Sep 2014 | B2 |
| 8834420 | Estes et al. | Sep 2014 | B2 |
| 8834454 | Genosar et al. | Sep 2014 | B2 |
| 8858511 | Gonnelli et al. | Oct 2014 | B2 |
| 8864739 | Moberg et al. | Oct 2014 | B2 |
| 8890380 | Andrieux et al. | Nov 2014 | B2 |
| 8900188 | Blumberg, Jr. et al. | Dec 2014 | B2 |
| 8905966 | Yoh et al. | Dec 2014 | B2 |
| 8905970 | Bates et al. | Dec 2014 | B2 |
| 8920367 | Edwards et al. | Dec 2014 | B2 |
| 8920376 | Caffey et al. | Dec 2014 | B2 |
| 8920386 | Cefai et al. | Dec 2014 | B2 |
| 8957674 | Genoud et al. | Feb 2015 | B2 |
| 8970384 | Yodfat et al. | Mar 2015 | B2 |
| 8998850 | Kamen et al. | Apr 2015 | B2 |
| 8998851 | Constantineau et al. | Apr 2015 | B2 |
| 9011371 | Moberg et al. | Apr 2015 | B2 |
| 9033925 | Moberg et al. | May 2015 | B2 |
| 9050406 | Kow et al. | Jun 2015 | B2 |
| 9061097 | Holt et al. | Jun 2015 | B2 |
| 9089637 | Chong et al. | Jul 2015 | B2 |
| 9107998 | Pratt et al. | Aug 2015 | B2 |
| 9107999 | Moberg et al. | Aug 2015 | B2 |
| 9180244 | Anderson et al. | Nov 2015 | B2 |
| 9227010 | Neta et al. | Jan 2016 | B2 |
| 9227019 | Swift et al. | Jan 2016 | B2 |
| 9238112 | Schoonmaker et al. | Jan 2016 | B2 |
| 9242052 | Pettis et al. | Jan 2016 | B2 |
| 9250111 | Whalley et al. | Feb 2016 | B2 |
| 9283322 | Shih et al. | Mar 2016 | B2 |
| 9327073 | Moberg et al. | May 2016 | B2 |
| 9333297 | Li et al. | May 2016 | B2 |
| 9344024 | Favreau | May 2016 | B2 |
| 9364608 | Moberg et al. | Jun 2016 | B2 |
| 9379652 | Favreau | Jun 2016 | B2 |
| 9379653 | Favreau | Jun 2016 | B2 |
| 9381299 | Kuo et al. | Jul 2016 | B2 |
| 9402950 | Dilanni et al. | Aug 2016 | B2 |
| 9402951 | Geipel et al. | Aug 2016 | B2 |
| 9415158 | Miller et al. | Aug 2016 | B2 |
| 9433732 | Moberg et al. | Sep 2016 | B2 |
| 9433733 | Moberg et al. | Sep 2016 | B2 |
| 9446185 | Yodfat et al. | Sep 2016 | B2 |
| 9452261 | Alon | Sep 2016 | B2 |
| 9463280 | Cabiri et al. | Oct 2016 | B2 |
| 9480624 | Holt et al. | Nov 2016 | B2 |
| 9492613 | Kamen et al. | Nov 2016 | B2 |
| 9492614 | Kamen et al. | Nov 2016 | B2 |
| 9498587 | Gray | Nov 2016 | B2 |
| 9504785 | Forsell et al. | Nov 2016 | B2 |
| 9545474 | Hanson et al. | Jan 2017 | B2 |
| 9592336 | Nielsen et al. | Mar 2017 | B2 |
| 9616171 | Qin et al. | Apr 2017 | B2 |
| 9623174 | Pang et al. | Apr 2017 | B2 |
| 9636451 | Gonnelli et al. | May 2017 | B2 |
| 9649433 | Lanier, Jr. et al. | May 2017 | B2 |
| 9662271 | Holt et al. | May 2017 | B2 |
| 9687186 | Goldstein et al. | Jun 2017 | B2 |
| 9717857 | Lanier | Aug 2017 | B2 |
| 9724462 | Rotem | Aug 2017 | B2 |
| 9744297 | Cabiri et al. | Aug 2017 | B2 |
| 9744304 | Swift et al. | Aug 2017 | B2 |
| 9750871 | Metzmaker et al. | Sep 2017 | B2 |
| 9750875 | Smith et al. | Sep 2017 | B2 |
| 9750953 | Kalafut | Sep 2017 | B2 |
| 9782545 | Gross et al. | Oct 2017 | B2 |
| 9795735 | Levesque et al. | Oct 2017 | B2 |
| 9812918 | Andrieux | Nov 2017 | B2 |
| 9813985 | Shapley et al. | Nov 2017 | B2 |
| 9821117 | Anderson et al. | Nov 2017 | B2 |
| 9849238 | Li et al. | Dec 2017 | B2 |
| 9861769 | Kamen et al. | Jan 2018 | B2 |
| 9861801 | Baker et al. | Jan 2018 | B2 |
| 9867929 | Searle et al. | Jan 2018 | B2 |
| 9878091 | Cabiri | Jan 2018 | B2 |
| 9881367 | Milne et al. | Jan 2018 | B1 |
| 9889256 | Cabiri et al. | Feb 2018 | B2 |
| 9901672 | Despa et al. | Feb 2018 | B2 |
| 9940440 | Ali et al. | Apr 2018 | B2 |
| 9943643 | Constantineau et al. | Apr 2018 | B2 |
| 9950110 | Mandro et al. | Apr 2018 | B2 |
| 9956345 | Anderson et al. | May 2018 | B2 |
| 9987428 | Tan-malecki et al. | Jun 2018 | B2 |
| 9999724 | Cindrich et al. | Jun 2018 | B2 |
| 10010674 | Rosinko et al. | Jul 2018 | B2 |
| 10029046 | Haueter et al. | Jul 2018 | B2 |
| 10034976 | Vazquez et al. | Jul 2018 | B2 |
| 10034977 | Haueter et al. | Jul 2018 | B2 |
| 10034983 | Haueter et al. | Jul 2018 | B2 |
| 10071209 | Solomon et al. | Sep 2018 | B2 |
| 10088660 | Fradkin et al. | Oct 2018 | B2 |
| 10092703 | Mounce et al. | Oct 2018 | B2 |
| 10092706 | Denzer et al. | Oct 2018 | B2 |
| 10112005 | Rotem et al. | Oct 2018 | B2 |
| 10124112 | Diianni et al. | Nov 2018 | B2 |
| 10130758 | Diianni et al. | Nov 2018 | B2 |
| 10141882 | Favreau | Nov 2018 | B2 |
| 10183156 | Ross et al. | Jan 2019 | B2 |
| 10195342 | Cole et al. | Feb 2019 | B2 |
| 10220147 | Constantineau et al. | Mar 2019 | B2 |
| 10228663 | Favreau | Mar 2019 | B2 |
| 10232108 | Qi et al. | Mar 2019 | B2 |
| 10245377 | Mclaughlin | Apr 2019 | B2 |
| 10272197 | Shapley et al. | Apr 2019 | B2 |
| 10272200 | Shapley et al. | Apr 2019 | B2 |
| 10279129 | Shay | May 2019 | B2 |
| 10314976 | Tan-malecki et al. | Jun 2019 | B2 |
| 10335542 | Rotem | Jul 2019 | B2 |
| 10342926 | Nazzaro et al. | Jul 2019 | B2 |
| 10363342 | Dillon et al. | Jul 2019 | B2 |
| 10363372 | Nazzaro | Jul 2019 | B2 |
| 10363374 | Nazzaro et al. | Jul 2019 | B2 |
| 10391237 | Cefai et al. | Aug 2019 | B2 |
| 10391239 | Lorenzen et al. | Aug 2019 | B2 |
| 10398854 | Fenster et al. | Sep 2019 | B2 |
| 10413665 | Rioux et al. | Sep 2019 | B2 |
| 10420883 | Diianni et al. | Sep 2019 | B2 |
| 10438696 | Shapley et al. | Oct 2019 | B2 |
| 10438698 | Pillalamarri et al. | Oct 2019 | B2 |
| 10441717 | Schmid et al. | Oct 2019 | B2 |
| 10441723 | Nazzaro | Oct 2019 | B2 |
| 10448885 | Schmid | Oct 2019 | B2 |
| 10449290 | Shapley et al. | Oct 2019 | B2 |
| 10478550 | Hadvary et al. | Nov 2019 | B2 |
| 10492990 | Mounce et al. | Dec 2019 | B2 |
| 10561797 | Nazzaro et al. | Feb 2020 | B2 |
| 10569014 | Hanson et al. | Feb 2020 | B2 |
| 10625018 | Destefano et al. | Apr 2020 | B2 |
| 10646652 | Mccullough et al. | May 2020 | B2 |
| 10668227 | Caspers | Jun 2020 | B2 |
| 10729852 | Baker et al. | Aug 2020 | B2 |
| 10737024 | Schmid | Aug 2020 | B2 |
| 10765801 | Mccullough | Sep 2020 | B2 |
| 10814062 | Gyory | Oct 2020 | B2 |
| 20030014014 | Nitzan | Jan 2003 | A1 |
| 20030065287 | Spohn et al. | Apr 2003 | A1 |
| 20030109827 | Lavi et al. | Jun 2003 | A1 |
| 20040010207 | Flaherty et al. | Jan 2004 | A1 |
| 20040013538 | Fuchs | Jan 2004 | A1 |
| 20040015042 | Vincent et al. | Jan 2004 | A1 |
| 20040064101 | Kowan et al. | Apr 2004 | A1 |
| 20040162521 | Bengtsson | Aug 2004 | A1 |
| 20050147508 | Luongo | Jul 2005 | A1 |
| 20050203461 | Flaherty et al. | Sep 2005 | A1 |
| 20080051738 | Griffin | Feb 2008 | A1 |
| 20090036867 | Glejboel et al. | Feb 2009 | A1 |
| 20090254041 | Krag et al. | Oct 2009 | A1 |
| 20100137830 | Glejboel et al. | Jun 2010 | A1 |
| 20100227818 | Bock et al. | Sep 2010 | A1 |
| 20100292632 | Mulvihill et al. | Nov 2010 | A1 |
| 20110230826 | Yoh et al. | Sep 2011 | A1 |
| 20120022499 | Anderson et al. | Jan 2012 | A1 |
| 20130090633 | Loeb | Apr 2013 | A1 |
| 20140088554 | Li | Mar 2014 | A1 |
| 20140142508 | Diianni et al. | May 2014 | A1 |
| 20140163477 | Quinn et al. | Jun 2014 | A1 |
| 20140214010 | Kuo et al. | Jul 2014 | A1 |
| 20150029816 | Beyer | Jan 2015 | A1 |
| 20150141920 | O'connor et al. | May 2015 | A1 |
| 20160000999 | Focht et al. | Jan 2016 | A1 |
| 20160177937 | Liu | Jun 2016 | A1 |
| 20160184516 | Shih et al. | Jun 2016 | A1 |
| 20160369789 | Alderete, Jr. et al. | Dec 2016 | A1 |
| 20170189609 | Wei | Jul 2017 | A1 |
| 20170281877 | Marlin et al. | Oct 2017 | A1 |
| 20180085517 | Laurence et al. | Mar 2018 | A1 |
| 20190151544 | Stonecipher | May 2019 | A1 |
| 20190365990 | Phillips et al. | Dec 2019 | A1 |
| 20200113515 | O'connor et al. | Apr 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 0223451 | May 1987 | EP |
| 0268480 | May 1988 | EP |
| 0293958 | Dec 1988 | EP |
| 0380862 | Aug 1990 | EP |
| 0464761 | Jan 1992 | EP |
| 0937477 | Aug 1999 | EP |
| 0555007 | Dec 1999 | EP |
| 2060284 | May 2009 | EP |
| 1677729 | Jul 2009 | EP |
| 2134388 | Dec 2012 | EP |
| 2902052 | Aug 2015 | EP |
| 3354303 | Aug 2018 | EP |
| 2000069507 | Nov 2000 | WO |
| 2007077255 | Jul 2007 | WO |
| 2008107378 | Sep 2008 | WO |
| 2010096449 | Aug 2010 | WO |
| 2012126744 | Sep 2012 | WO |
| 2013184646 | Dec 2013 | WO |
| 2015038556 | Mar 2015 | WO |
| 2015048093 | Apr 2015 | WO |
| 2016164349 | Oct 2016 | WO |
| 2017192287 | Nov 2017 | WO |
| 2019159121 | Aug 2019 | WO |
| Entry |
|---|
| An International Search Report and a Written Opinion both dated Jan. 19, 2018, which issued during the prosecution of Applicant's PCT/IL2017/051276. |
| Extended European Search Report dated Sep. 11, 2020 in European Application No. 20187553.1. |
| An International Search Report and a Written Opinion both dated Jun. 9, 2020, which issued during the prosecution of PCT/IL2020/050246. |
| European Search Report dated Dec. 12, 2019, which issued during the prosecution of Applicant's European App No. 19201363.9. |
| U.S. Appl. No. 61/940,601, filed Feb. 17, 2014. |
| An Office Action dated Dec. 3, 2021, which issued during the prosecution of U.S. Appl. No. 16/591,848. |
| Number | Date | Country | |
|---|---|---|---|
| 20190365985 A1 | Dec 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62425105 | Nov 2016 | US |
